Drägerwerk stock rises before Xetra after stronger nine-month sales

Published on 11/11/2026 at 18:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Drägerwerk stock gains ground before Xetra after stronger orders and sales. The company still faces pressure on quarterly profitability.

Sales growth meets margin pressure

Nine-month sales and order intake increased, led by stronger demand in Safety Technology.
Third-quarter EBIT declined as personnel, logistics and IT costs increased faster than sales.
Drägerwerk kept its 2026 sales and EBIT-margin outlook unchanged ahead of its November 18 Capital Markets Day.

Drägerwerk, DE0005550636, Illustration mit AI erstellt.

Drägerwerk stock traded at 102.10 euros on Lang & Schwarz at 08:57 CET on Wednesday, November 11, 2026, 2.41 percent above the Xetra close of Tuesday, November 10. That is 2.56 percent above the 99.55 euros cited in our previous report at 17:10 CET on Tuesday.

Stronger demand, weaker quarter

Drägerwerk reported its nine-month results on October 29, 2026. In the release carried by Finanzen.net, currency-adjusted order intake rose 3.6 percent to 2,673.5 million euros and sales increased 5.3 percent to 2,453.9 million euros.

Both divisions contributed to sales growth. Medical Technology advanced 4.4 percent to 1,367.0 million euros, while Safety Technology rose 6.5 percent to 1,087.0 million euros. Safety Technology also provided the stronger order signal, with nine-month order intake up 13.1 percent.

One-off effects cloud earnings quality

Group EBIT increased to 111.8 million euros from 77.1 million euros, lifting the nine-month margin to 4.6 percent. The result included 27.9 million euros in customs refunds, including 20.1 million euros attributable to the third quarter.

The quarterly picture was less supportive. Third-quarter sales increased 1.0 percent to 850.8 million euros, but EBIT fell to 48.0 million euros from 56.7 million euros and the margin narrowed to 5.6 percent from 6.8 percent. Higher personnel, logistics and IT costs weighed on profitability.

Outlook unchanged before strategy event

Drägerwerk retained its 2026 forecast for currency-adjusted sales growth of 2.0 to 6.0 percent and an EBIT margin of 6.0 to 8.0 percent. The next strategic milestone is the Capital Markets Day on November 18, 2026, in Lübeck, where management plans to present its Ambition 2030.

German equities provide the broader market backdrop for Drägerwerk stock, with the DAX as the relevant domestic benchmark.

Further developments can be followed in More news and analyses on Drägerwerk stock.